Icosavax (ICVX) Stock Price, News & Analysis

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key Stats

• Today's Range: $15.31 to $15.31
• 50-Day Range: $15.31 to $15.45
• 52-Week Range: $4.75 to $16.10
• Volume: N/A
• Average Volume: 1.22 million shs
• Market Capitalization: $766.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ICVX Stock Analysis - Frequently Asked Questions

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to analyst estimates of $3.30 million.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

What other stocks do shareholders of Icosavax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Icosavax investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ICVX
• CUSIP: N/A
• CIK: 1786255
• Web: icosavax.com
• Phone: 206-737-0085
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $28.00
• High Stock Price Target: $28.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: +82.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-91,760,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.06%
• Return on Assets: -39.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.06
• Quick Ratio: 18.06

Sales & Book Value

• Annual Sales: $580,000.00
• Price / Sales: 1,322.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.47 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 50,090,000
• Free Float: 34,767,000
• Market Cap: $766.88 million
• Optionable: Optionable
• Beta: 1.28